Vaxils VaxHit™ platform technology combines proprietary algorithms which enable in-silico identification of signal peptides domains and their subsequent use as immunotherapeutic products, essentially a launchpad for unique and specific targeted immunotherapy products.
VaxHit’s novelty includes its ability to identify and select immunotherapies which cause a robust immune response, with T-Cells – CD4+ (Helper T-cells and CD8+ (Killer T-cells) and B-cell producing antibodies as well. This immune response may be directed against cancer cells, or in the case where the patient is suffering from an infectious disease, against the relevant pathogen.
In addition, VaxHit-derived potential immunotherapies offer the unique potential to cope with attempts by cancer cells and/or other pathogens to seek to evade the immune system's response against them. As well as identifying potential VCs for use in therapeutic and prophylactic situations against cancer and infectious diseases. More recently
Vaxil has demonstrated the ability of its VaxHit technology to isolate superior antibodies against key SP domains. This has a variety of applications both in the fields of diagnostics and therapy for both cancer and infectious diseases.